Research · Sep 3, 2026
[PCVX] Vaxcyte Thesis 2026: VAX-31 Pneumococcal Phase 3 Drives Pre-Commercial Cash Runway
Vaxcyte, Inc. (NASDAQ: PCVX) FY2025 revenue ~$0M (pre-commercial) with adj. operating loss ~$(550-650M) + adj. EPS ~$(4.20-4.95) reflecting continued pre-commercial Carrier-Free Pneumococcal Conjugate Vaccine (PCV) + Group A Streptococcus + Periodontitis vaccine pipeline (selected primary VAX-24 + VAX-31 Pneumococcal Phase 3 + VAX-A1 Group A Strep + VAX-PG Periodontitis preclinical/Phase 1) under continued Co-Founder + President + CEO Grant Pickering since 2013 (~12-year founding tenure; selected primary post-2013 founding architect with co-founder Jeff Fairman). One of the largest US specialty pre-commercial Carrier-Free Pneumococcal Conjugate Vaccine + Group A Streptococcus + Periodontitis vaccine biotech companies. Founded 2013 as SutroVax (Pfenex spin-off subsidiary) by Grant Pickering + Jeff Fairman in San Carlos California (~12-year heritage; selected pioneer Carrier-Free Pneumococcal Conjugate Vaccine using Cell-Free Protein Synthesis platform; selected post-2020 SutroVax rebranded to Vaxcyte); selected post-June 2020 NASDAQ IPO; selected post-2020-2025 ~$3B+ cumulative equity raises; selected post-Q4 2024 VAX-24 Phase 2 adult readout positive; selected post-2025 VAX-31 Phase 3 enrollment. Headquartered in San Carlos California; ~600-700 employees globally with ~30-35% Founders + Abingworth + RA Capital + Forester Diagnostics aggregate institutional ownership. One primary business: Pre-commercial Carrier-Free PCV + Group A Strep + Periodontitis vaccine biotech ~100%. Geographic mix: US ~99%+ (R&D + Phase 3 enrollment). VAX-31 + VAX-24 Pneumococcal Conjugate Vaccine pipeline (key 2026-2028 catalyst): selected continued post-2024 VAX-24 Pneumococcal (24-valent Carrier-Free PCV; post-Q4 2024 Phase 2 adult readout positive); selected primary post-2024 VAX-31 Pneumococcal (31-valent Carrier-Free PCV; Phase 3 enrollment + expected Phase 3 readout 2026-2027); selected Pfizer Prevnar 20 (PCV20) + Merck Capvaxive (V116) competitor benchmarking; selected ~$8-10B global Pneumococcal Conjugate Vaccine TAM; selected ~$3-5B US PCV TAM. Group A Strep + Periodontitis + Pediatric pipeline: selected continued post-2024 VAX-A1 Group A Streptococcus (preclinical + Phase 1 enrollment; first Group A Strep vaccine pipeline; ~$1-2B global TAM); selected VAX-PG Periodontitis (preclinical; ~$1-2B global TAM); selected VAX-Pediatric Pneumococcal Conjugate Vaccine (preclinical; Pediatric PCV ~$3-4B TAM). Co-Founder + President + CEO Grant Pickering since 2013 (~12-year founding tenure); CFO Andrew Guggenhime. Capital position: ~$0 dividend (no dividend track post-June 2020 NASDAQ IPO); minimal opportunistic buybacks; aggregate capital return ~$0M FY2025; net cash ~$3.0-3.4B aggregate cash + investments balance; net leverage ~negligible (~debt-light); non-investment grade unrated credit; ~130-135M diluted shares. FY2026 thesis: VAX-31 Pneumococcal Phase 3 Pre-Commercial pipeline + Group A Strep + Periodontitis + Pediatric pipeline + ~$3.0-3.4B aggregate cash runway through FY2027-FY2028 + ~$8-10B aggregate global PCV TAM + ~$3-5B aggregate US PCV TAM + post-VAX-24 Phase 2 positive read-through. Risks: Pfizer (Prevnar 20 PCV20 commercial) + Merck (Capvaxive V116 commercial) + selected various aggregate global PCV competitive displacement + VAX-31 Phase 3 readout timing (delays = direct cash runway risk; ~$0.50-1.50 operating loss expansion per ~6-month delay) + ACIP recommendation cycle considerations + post-2024 VAX-24 Phase 2 read-through validity considerations + Phase 1 + preclinical advancement timing considerations + Federal Reserve interest rate cycle considerations + Founders + institutional ownership governance considerations + post-June 2020 NASDAQ IPO overhang considerations + Cell-Free Protein Synthesis platform technology considerations.